IGHE and allergic asthma: Previously, systemic use of anti-IgE monoclonal antibody (rhuMAb-E25; later licensed as omalizumab) in individuals with allergic asthma has been shown to significantly reduce serum IgE as well as the LAR (vs. placebo) [43,45].